SAIT301 is a monoclonal humanized antibody developed by Samsung that promotes c-MET degradation.1226,1231 SAIT301 inhibits nasopharyngeal cell invasion and migration by downregulating EGR-1 via the degradation of c-MET.1232 Its clinical phase I trial in c-MET-overexpressed metastatic CRC has been completed, and the most common adverse effects were decreased appetite (50.0%), hypophosphatemia, fatigue, and dizziness (25.0%), diarrhea, and dyspnea (18.8%).1233 ABT-700 (h224G11) is a humanized bivalent mAb that inhibits c-MET dimerization and activation. The gene discussed is MET; the disease is hypophosphatemia.